Hepion Pharmaceuticals, Inc.
Other OTCTotal Valuation
Hepion Pharmaceuticals, Inc. carries a market capitalization of 698,622.00, placing it among publicly traded companies globally. Its enterprise value stands at -252,950.22, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 698,622.00 |
| Enterprise Value | -252,950.22 |
Share Statistics
Hepion Pharmaceuticals, Inc. currently has 11.62M shares outstanding.
| Shares Outstanding | 11.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | 4.05 |
| P/FCF Ratio | -0.42 |
| P/OCF Ratio | -0.42 |
Financial Position
Hepion Pharmaceuticals, Inc. maintains a current ratio of 3.68, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.68 |
| Quick Ratio | 3.54 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,540.09 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -66.11 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Hepion Pharmaceuticals, Inc.'s stock has gained approximately 42.85714% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.06.
| Beta (5Y) | N/A |
| 52-Week Price Change | 42.85714% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.06 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -3.28M, while operating income came in at -3.28M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -3.28M |
| Pretax Income | -2.98M |
| Net Income | -2.98M |
| EBITDA | -3.28M |
| EBIT | -3.28M |
| Earnings Per Share (EPS) | -0.26 |
Balance Sheet
Total book value stands at -246.91M, with working capital of 1.97M providing operational flexibility.
| Cash & Cash Equivalents | 2.60M |
| Total Debt | N/A |
| Net Debt | -2.60M |
| Equity (Book Value) | -246.91M |
| Book Value Per Share | -21.43 |
| Working Capital | 1.97M |
Cash Flow
Hepion Pharmaceuticals, Inc. produced -1.58M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.58M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.58M |
| FCF Per Share | -0.14 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 42.20 |
| FCF Yield | -240.72 |
Stock Splits
Hepion Pharmaceuticals, Inc.'s most recent stock split took place on March 18, 2025 with a 50:1 split ratio.
| Last Split Date | 3/18/2025 |
| Split Ratio | 50:1 |
Scores
Hepion Pharmaceuticals, Inc. posts an Altman Z-Score of -130.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -130.43 |